Cancer drugs duty waiver to benefit only AstraZeneca

Q: How long will it take to read this news story?

The story "Cancer drugs duty waiver to benefit only AstraZeneca" has 627 words across 20 sentences, which will take approximately 3 - 6 minutes for the average person to read.

Q: Which news outlet covered this story?

The story "Cancer drugs duty waiver to benefit only AstraZeneca" was covered 1 days ago by Times of India, a news publisher based in India.

Q: How trustworthy is 'Times of India' news outlet?

Times of India is a fully independent (privately-owned) news outlet established in 1838 that covers mostly economy and business news. The outlet is headquartered in India and publishes an average of 10 news stories per day. It's most recent story was published 7 hours ago.

Q: What do people currently think of this news story?

The sentiment for this story is currently Neutral, indicating that people are not responding positively or negatively to this news.

Q: How do I report this news for inaccuracy?

You can report an inaccurate news publication to us via our contact page. Please also include the news #ID number and the URL to this story.<ul><li>News ID: #21768103</li><li>URL: https://beamstart.com/news/cancer-drugs-duty-waiver-to-17218790101875</li></ul>

Times of India 1d ago

Cancer drugs duty waiver to benefit only AstraZeneca - Times of India

Quick Summary:

India Business News: NEW DELHI: The Budget proposal to waive customs levy on three specific cancer therapies has sparked claims of being "an eye-wash" and "selective", as .

A business journalist with around two decades of experience tracking key consumer-focussed sectors like consumer durables, retail, consumer goods, aviation, automobiles and advertising, as well as economic ministries of the Union government.

Trastuzumab Deruxtecan is a breast cancer drug, Osimertinib lung cancer and Durvalumab is used as lung and biliary tract cancer therapy.